Liver Research Unit, Medica Sur Clinic & Foundation, Mexico City, Mexico; Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.
Departamento de Gastroenterología, Facultad de Medicina, and Centro de Envejecimiento y Regeneracion (CARE), Departamento de Biologia Celular y Molecular, Facultad de Ciencias Biologicas, Pontificia Universidad Catolica de Chile, Santiago, Chile.
Lancet Gastroenterol Hepatol. 2021 Jan;6(1):65-72. doi: 10.1016/S2468-1253(20)30340-X. Epub 2020 Nov 9.
The Latin American Association for the Study of the Liver (Asociación Latinoamericana para el Estudio del Hígado; ALEH) represents liver professionals in Latin America with the mission of promoting liver health and quality patient care by advancing the science and practice of hepatology and contributing to the development of a regional health policy framework. Fatty liver disease associated with metabolic dysfunction is of specific concern in the ALEH region, where its prevalence is one of the highest globally, second only to the Middle East. A recent consensus from an international panel recommended a new definition of fatty liver disease associated with metabolic dysfunction, including a shift in name from non-alcoholic fatty liver disease (NAFLD) to metabolic-associated fatty liver disease (MAFLD), and adoption of a set of positive criteria to diagnose the disease, independent of alcohol intake or other liver diseases. Given, the importance of this proposal, ALEH invited leading members of regional nations to come to a consensus on it from a local perspective. We reached a consensus to endorse the proposal that the disease should be renamed as MAFLD and that the disease should be diagnosed by the proposed simple and easily applicable criteria. We expect that this change in nosology will result in improvements in disease awareness and in advances in scientific, economic, public health, political, and regulatory aspects of the disease.
拉丁美洲肝脏研究学会(Asociación Latinoamericana para el Estudio del Hígado; ALEH)代表拉丁美洲的肝脏专业人士,使命是通过推进肝脏病学的科学和实践,以及为制定区域卫生政策框架做出贡献,促进肝脏健康和提高患者护理质量。与代谢功能障碍相关的脂肪肝疾病在 ALEH 地区尤为令人关注,该地区的患病率是全球最高的地区之一,仅次于中东。最近,一个国际专家组的共识建议对与代谢功能障碍相关的脂肪肝疾病采用一个新的定义,包括名称从非酒精性脂肪性肝病(NAFLD)改为代谢相关性脂肪性肝病(MAFLD),并采用一套独立于酒精摄入或其他肝脏疾病的阳性标准来诊断该疾病。鉴于该建议的重要性,ALEH 邀请该地区主要国家的成员从当地角度对该建议达成共识。我们达成了共识,支持将该疾病重新命名为 MAFLD 的建议,以及根据拟议的简单且易于应用的标准诊断该疾病的建议。我们期望这种分类学的改变将提高对该疾病的认识,并在疾病的科学、经济、公共卫生、政治和监管方面取得进展。